Announcements Trials
Browse Landscape

Status

Completed 59Active not recruiting 35Recruiting 33Unknown 26Terminated 25Withdrawn 16Not yet recruiting 5Approved for marketing 2

Sponsor Class

INDUSTRY 2

Study Type

Expanded_access 2

Sponsor

Cancer Type

Gynecologic 1Genitourinary 1

Conditions

Ovarian Neoplasms 1Metastatic Castration-resistant Prostate Cancer 1

Interventions

Afatinib 33-Iodobenzylguanidine 3niraparib 2lenvatinib 2ibrutinib 2gallium 68 PSMA-11 2abemaciclib 2Trastuzumab 2Sunitinib 2Ramucirumab 2Oxaliplatin 2Magnetic Resonance Spectroscopy 2Gefitinib 2Fluorouracil 2Capecitabine 2Amifampridine 2Abiraterone Acetate 2zenocutuzumab 1vorasidenib 1tucatinib 1trilaciclib 1trifluridine tipiracil drug combination 1tovorafenib 1talquetamab 1tafasitamab 1selpercatinib 1sacituzumab govitecan 1ripretinib 1pralsetinib 1ponatinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Approved for marketing × niraparib × Clear all
NCT05401214 2025-06-13

Pre-approval Access Single Patient Request for Niraparib / Abiraterone Acetate Combination (Nira/AA Combination)

Janssen Research & Development, LLC

Approved for marketing
Genitourinary

Metastatic Castration-resistant Prostate Cancer

NCT03025867 2017-04-17

Expanded Access Protocol for Niraparib in Patients With Recurrent Ovarian Cancer

Tesaro, Inc.

Approved for marketing
Gynecologic

Ovarian Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡